Brian Taylor Slingsby insider trades: Mineralys Therapeutics (MLYS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Brian reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | MLYS | ↓ Sell | 104,320 | $28.81 | $3.0M | Indirect | Sep 24, 2026 (2d) |
| Nov 20, 2025 | MLYS | ↓ Sell | 1,000,000 | $43.35 | $43.4M | Indirect | Nov 21, 2025 (1d) |
| Mar 13, 2025 | MLYS | ↑ Buy | 259,259 | $13.50 | $3.5M | Indirect | Apr 25, 2025 (43d) |
| Jul 24, 2024 | MLYS | ↓ Sell | 550,000 | $13.05 | $7.2M | Indirect | Jul 26, 2024 (2d) |
| Feb 14, 2023 | MLYS | ↑ Buy | 250,000 | $16.00 | $4.0M | Indirect | Feb 16, 2023 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MLYS insiders
Open-market trades in the last 12 months
About Brian Taylor Slingsby's insider trades
Brian Taylor Slingsby is a director at Mineralys Therapeutics (MLYS). Since Feb 14, 2023, Brian has reported 2 open-market purchases worth $7.5M and 3 sales worth $53.5M on SEC Form 4. In the last 12 months: 2 sales ($46.4M).
Their filings also include other transactions (4 filings), grants and awards (4 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MLYS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.